Evaluation of the safety of intravesical BCG therapy in France: analysis of serious adverse events notified over a three-year period

Objectives: Intravesical BCG therapy remains the first-line prophylactic treatment for recurrences of superficial bladder tumours. However necessary the safety, of this medicinal product, for which a potential risk of complications was demonstrated during development, needs to be evaluated.


Published in:
Progres En Urologie, 11, 458-465
Year:
2001
Keywords:
Laboratories:




 Record created 2011-09-29, last modified 2018-03-17


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)